Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

COYA 302

Other · developed by Coya Therapeutics

Phase 2/3 Most advanced trial

COYA Developer

1 Registered trials

What is COYA 302?

COYA 302 is an investigational agent studied in amyotrophic lateral sclerosis (ALS).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Coya Therapeutics (COYA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07161999	Phase 2/3	Amyotrophic Lateral Sclerosis (ALS)	Recruiting	COYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral Sclerosis (ALS)

Sources

ClinicalTrials.gov NCT07161999

Updated Oct 11, 2026. Something wrong or missing? Report it on the COYA page.

Follow COYA, the company behind COYA 302

See COYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COYA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z